September 21, 2023
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
Amsterdam, The Netherlands
argenx SE today announced that Health Canada has issued a Notice of Compliance authorizing VYVGARTⓇ (efgartigimod alfa) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Get photos, fact sheets, illustrations and more.
Join the team
Dare to do more with a thriving career at Argenx.
Get the latest news and info via our social media channels.